WINDTREE THERAPEUTICS INC DE (WINTW)
WINDTREE THERAPEUTICS INC DE (WINTW)
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -42,761 | NaN |
| In-process research and development expenses in connection with the varian asset acquisition-Varian Asset Acquisition | 0 | 0 |
| Unrealized loss (gain) on foreign exchange rate changes | NaN | -580 |
| Depreciation and amortization | 360 | 34 |
| Stock-based compensation | 17 | 104 |
| Non-cash lease expense | -227 | 227 |
| Accretion of discount on senior note receivable | -757 | -195 |
| Amortization of debt discount and debt issuance costs | 179 | 0 |
| Non-cash expense related to equity consideration for services | 0 | NaN |
| Loss on eloc commitment note and derivative liability | -14,965 | 0 |
| Loss on impairment of intangible assets | 16,130 | NaN |
| Loss on sale and disposal of property and equipment | 0 | NaN |
| Loss on settlement of deposit | -650 | NaN |
| Loss on debt issuances | 0 | -7,437 |
| Gain on debt extinguishment | 52 | NaN |
| Deferred income tax benefit | -3,226 | NaN |
| Unrealized loss (gain) on foreign exchange rate changes | -376 | NaN |
| Change in fair value of convertible notes | 3,473 | NaN |
| Change in fair value of derivative liabilities | 613 | 188 |
| Change in fair value of senior secured notes | 0 | 0 |
| Change in fair value of warrant liability | -292 | NaN |
| Prepaid expenses and other current assets | 5 | -532 |
| Accounts payable | -2,472 | 2,244 |
| Accrued expenses | 23 | 99 |
| Operating lease liabilities | -128 | -249 |
| Other current liabilities | -240 | 66 |
| Net cash used in operating activities | -6,372 | -5,064 |
| Issuance of senior note | 789 | 3,783 |
| Deposit | 0 | 1,400 |
| Proceeds from sale of property and equipment | 0 | NaN |
| Purchase of property and equipment | 0 | 0 |
| Proceeds from atm program, net of issuance costs-ATMProgram | NaN | 0 |
| Net cash used in investing activities | -789 | -5,183 |
| Proceeds from convertible notes | 70 | 4,233 |
| Proceeds from private placement of series d preferred stock, net of issuance costs-Series DPreferred Stock Mezzanine Equity | 0 | 2,813 |
| Proceeds from eloc purchase agreement, net of issuance costs-Eloc Purchase Agreement | 13,446 | 2,403 |
| Proceeds from private placement of series d preferred stock, net of issuance costs-Private Placement | 0 | NaN |
| Proceeds from senior secured notes payable | 0 | 500 |
| Proceeds from exercise of common stock warrants | 26 | 327 |
| Principal payments on senior secured notes payable | 0 | 600 |
| Principal payments on loans payable | 407 | NaN |
| Redemptions of series c preferred stock-Series CPreferred Stock | 517 | NaN |
| Cash dividend payments on series c preferred stock | 0 | 90 |
| Redemptions of series c preferred stock-Series DPreferred Stock | 4,171 | NaN |
| Proceeds from atm program, net of issuance costs | 0 | NaN |
| Proceeds from senior convertible notes payable, net of issuance costs | 0 | NaN |
| Principal payments on senior convertible notes payable | 2,200 | NaN |
| Proceeds from senior secured and unsecured notes, net of issuance costs | 0 | 0 |
| Principal payments on loans payable | NaN | 333 |
| Issuance costs related to series b preferred stock | 0 | 0 |
| Redemptions of series c preferred stock | NaN | 483 |
| Payments on debt extinguishment | 0 | 0 |
| Net cash provided by financing activities | 7,063 | 8,770 |
| Net decrease in cash, cash equivalents, and restricted cash | -97 | -1,477 |
| Cash and cash equivalents at beginning of period | 1,788 | NaN |
| Cash and cash equivalents at end of period | 214 | NaN |